Inaktiver Wert

Andere Sprachen AEterna Zentaris Inc. Nasdaq

Aktien

CA0079753038

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

15.05.	MT Newswires Kanada Über Nacht zu beobachtende Aktien: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	MT
15.05.	Aeterna Zentaris Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17.05.
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17.05.
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro	17.05.
Aeterna Zentaris : Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 - Form 6-K	16.05.
Aeterna Zentaris : Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 - Form 6-K	15.05.
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	15.05.
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Aeterna Zentaris Reports First Quarter 2024 Financial Results	15.05.
Aeterna Zentaris : MATERIAL CHANGE REPORT - Form 6-K	09.05.
Aeterna Zentaris Announces Effective Date of Share Consolidation	01.05.
North American Morning Briefing : Powell Awaited -2-	03.04.
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28.03.
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28.03.
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27.03.
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27.03.
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27.03.
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	27.03.
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K	27.03.
Aeterna Zentaris : Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 - Form 6-K	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AEterna Zentaris Inc. Nasdaq

Aktien

CA0079753038

Andere Sprachen

Filter